An ANCA test helps evaluate whether symptoms could come from a group of small-vessel inflammatory diseases called ANCA-associated vasculitis. A positive result can raise concern, especially when it identifies proteinase 3 (PR3) or myeloperoxidase (MPO) antibodies and the patient has kidney, lung, sinus, skin, eye, or nerve findings that fit. A negative result makes classic granulomatosis with polyangiitis or microscopic polyangiitis less likely, but it cannot rule out every case. The reported pattern—c-ANCA, p-ANCA, or atypical ANCA—adds context but is less specific than the PR3 or MPO target. The most important point is that ANCA is neither a universal vasculitis screen nor a diagnosis by itself. Its meaning changes sharply with the reason for testing. An unexpected weak positive in a person without organ abnormalities is very different from a strong PR3 or MPO result in someone with red blood cell casts, lung bleeding, or destructive airway disease.
- A positive PR3-ANCA or MPO-ANCA result increases vasculitis risk most when symptoms and organ tests are compatible.
- c-ANCA commonly corresponds to PR3 antibodies, while p-ANCA commonly corresponds to MPO antibodies, but the pattern and antigen do not always match.
- A negative ANCA test does not exclude localized GPA, many cases of EGPA, or ANCA-negative pauci-immune kidney disease.
- Weak or atypical positives often have causes other than vasculitis, including inflammatory bowel disease, autoimmune liver disease, infection, and certain medications.
- Urgent evaluation is needed for coughing blood, rapidly rising creatinine, dark or bloody urine, falling urine output, severe breathing difficulty, or new focal nerve weakness.
Table of Contents
- What a Positive ANCA Test Means
- What a Negative ANCA Test Means
- How Patterns and PR3/MPO Antigens Fit Together
- How ANCA Changes the Estimated Risk of Vasculitis
- Other Causes of a Positive ANCA Result
- Repeat Testing, Trends, and Disease Monitoring
- Next Steps After an ANCA Result
What a Positive ANCA Test Means
A positive ANCA test means the laboratory detected antibodies that react with proteins in neutrophils. It does not automatically mean that blood vessels are inflamed. The result becomes more specific when the laboratory identifies PR3 or MPO and when the patient has objective features of ANCA-associated vasculitis (AAV).
ANCA reports can contain several kinds of positive findings:
- an IFA pattern, such as c-ANCA, p-ANCA, or atypical ANCA;
- a titer, such as 1:40 or 1:160;
- a PR3-ANCA concentration;
- an MPO-ANCA concentration;
- an interpretation such as borderline, low positive, moderate positive, or strong positive.
The numerical value must be read against that laboratory’s reference range. Different manufacturers use different units, antigens, calibration systems, and cutoffs. A value of 20 units on one assay may not equal 20 units on another.
A strong antigen-specific result generally has more diagnostic weight than a weak result near the cutoff. Even so, no number is a stand-alone severity score. A patient can have severe organ inflammation with a modest antibody value, or a high antibody value without active organ damage.
The clearest positive profiles are PR3-ANCA in a patient with a GPA-like presentation and MPO-ANCA in a patient with an MPA-like presentation. The dedicated PR3-ANCA interpretation and MPO-ANCA interpretation help distinguish the antigen from the older IFA pattern labels.
A positive result should trigger a search for evidence of affected organs, not an automatic prescription for immunosuppression. Infection and drug-induced autoimmunity can mimic AAV, and treating those conditions as primary vasculitis can cause harm.
What a Negative ANCA Test Means
A negative ANCA test lowers the probability of GPA and MPA, particularly when high-quality PR3 and MPO immunoassays are negative. It does not reduce the probability to zero.
Several clinically important situations can produce negative results:
Localized GPA: Disease limited mainly to the nose, sinuses, ears, orbit, or airway is less consistently ANCA-positive than severe systemic disease. Persistent bloody crusting, septal damage, subglottic narrowing, orbital inflammation, or unexplained lung nodules may still require imaging and biopsy.
EGPA: Many people with eosinophilic granulomatosis with polyangiitis are ANCA-negative. Asthma, marked eosinophilia, sinus disease, neuropathy, lung infiltrates, cardiac disease, and eosinophilic tissue inflammation carry more diagnostic weight than a negative ANCA result.
ANCA-negative pauci-immune glomerulonephritis: A kidney biopsy can show the same necrotizing, crescentic, low-immune-deposit pattern associated with AAV even when circulating ANCA is not detected. This condition can progress rapidly and needs specialist treatment.
Early disease or treatment effect: Antibody concentrations may be below the assay cutoff early in illness or after glucocorticoids and other immunosuppressive medicines have begun.
Method limitations: A test may measure only PR3 and MPO, use an insensitive platform for a particular antibody, or report IFA without antigen-specific testing. A negative result is only as broad as the method used.
A compelling pulmonary-kidney syndrome should therefore be evaluated urgently despite a negative result. The differential includes ANCA-negative AAV, anti-GBM disease, lupus, immune-complex vasculitis, infection, and other causes of rapidly progressive glomerulonephritis. The anti-GBM test is especially important when lung bleeding and kidney injury occur together.
How Patterns and PR3/MPO Antigens Fit Together
The IFA pattern describes where antibodies fluoresce on fixed neutrophils. PR3 and MPO assays identify the molecular target. Antigen specificity is generally more useful for classifying AAV than the pattern alone.
| Finding | Most common match | Typical association | Main caution |
|---|---|---|---|
| c-ANCA pattern | PR3-ANCA | GPA | Confirm PR3; pattern alone is not diagnostic |
| p-ANCA pattern | MPO-ANCA | MPA, renal-limited AAV, some EGPA | Many non-MPO antibodies and ANA can imitate this pattern |
| Atypical ANCA | Often neither PR3 nor MPO | IBD, autoimmune liver disease, infection, other immune states | Usually has low specificity for GPA or MPA |
| PR3 positive, IFA negative | PR3 antigen detected | Possible PR3-AAV | Consider strength, assay quality, and clinical fit |
| MPO positive, IFA negative | MPO antigen detected | Possible MPO-AAV | Review medication and nonvasculitic causes |
A classic c-ANCA pattern is diffuse and granular through the cytoplasm, often with stronger fluorescence between nuclear lobes. A classic p-ANCA pattern concentrates around the nucleus because ethanol fixation causes some positively charged granule proteins, including MPO, to migrate toward the nuclear membrane.
The ANCA IFA pattern can be useful when the antigen result is uncertain, when an atypical antibody is clinically relevant, or when the laboratory uses IFA as part of a reflex algorithm. It can also create confusion. Strong antinuclear antibodies may resemble p-ANCA, and non-PR3/non-MPO antibodies can produce perinuclear or atypical staining.
A result is called concordant when the expected pattern and antigen appear together, such as c-ANCA with PR3 or p-ANCA with MPO. Discordant results are not automatically false. They require review of assay strength, medications, ANA status, infection, and the reason for testing.
How ANCA Changes the Estimated Risk of Vasculitis
The probability of vasculitis after testing depends on the probability before testing. This is the practical meaning of pretest probability.
Consider two patients with the same low-positive MPO result. One has fatigue and an otherwise normal evaluation. The other has rapidly rising creatinine, dysmorphic red blood cells, red cell casts, lung infiltrates, and falling hemoglobin. The second patient has a far higher chance of MPO-associated vasculitis because the antibody aligns with a characteristic organ pattern.
| Context | Examples | How much a positive ANCA matters |
|---|---|---|
| High clinical probability | Glomerulonephritis, pulmonary hemorrhage, destructive upper-airway disease, mononeuritis multiplex | Substantially strengthens the case, especially if PR3 or MPO is strongly positive |
| Intermediate probability | Unexplained lung nodules, purpura, chronic sinus disease with systemic inflammation | Helps direct imaging, urine studies, specialist review, and biopsy |
| Low probability | Fatigue, diffuse pain, isolated high ESR, no objective organ abnormalities | A weak or atypical positive is more likely to be incidental or nonvasculitic |
The highest-yield indications for testing include rapidly progressive glomerulonephritis, pulmonary hemorrhage, pulmonary-kidney syndrome, chronic destructive airway disease, multiple lung nodules, palpable purpura with systemic illness, scleritis, and mononeuritis multiplex. A focused vasculitis blood test panel often accompanies urinalysis and organ-specific testing.
Sensitivity and specificity do not tell an individual patient’s risk without context. High specificity means a result is uncommon among people without the target disease in the studied population. It does not mean every positive result has a 98% chance of being vasculitis. Positive predictive value falls when testing is used in populations where AAV is rare.
Biopsy remains important when it can safely confirm the type of inflammation, assess damage, or exclude a mimic. A kidney biopsy, for example, distinguishes pauci-immune glomerulonephritis from immune-complex disease and can show how much tissue is acutely inflamed versus chronically scarred.
When ordering ANCA is most and least useful
ANCA testing is most useful when a clinician can name the organ process being investigated. Examples include glomerular hematuria with a rising creatinine, diffuse lung bleeding, unexplained cavitary nodules, persistent destructive sinus disease, scleritis, palpable purpura, or a painful asymmetric neuropathy. In those settings, a PR3 or MPO result can shorten the path to specialist evaluation and help prioritize biopsy.
The test is less useful as a broad search for the cause of fatigue, generalized aches, a mildly elevated CRP, or nonspecific tingling. AAV is uncommon, so testing many low-risk people inevitably produces weak positives that are not caused by vasculitis. The resulting label can lead to repeated blood draws, anxiety, imaging, or even unsafe treatment if the clinical mismatch is overlooked.
Age and background illness also affect interpretation. Older adults may have kidney disease, anemia, or lung abnormalities from common causes that resemble parts of AAV. People with chronic infection, inflammatory bowel disease, autoimmune liver disease, or exposure to certain drugs have a higher chance of nonvasculitic ANCA positivity. In these groups, the antibody must be matched carefully to urine sediment, imaging, cultures, medication history, and tissue findings.
A useful test request therefore states the suspected syndrome and includes relevant clinical details. This allows the laboratory to choose the appropriate reflex algorithm and helps the clinician interpret a borderline or discordant result. ANCA should answer a defined question, not substitute for defining the question first.
Screening also becomes less informative after another diagnosis already explains the findings. For example, a patient with culture-proven endocarditis, immune-complex glomerulonephritis, and a low-positive ANCA still needs treatment for infection; the antibody does not automatically create a second diagnosis of primary vasculitis. Likewise, an atypical ANCA in established ulcerative colitis may support the broader immune context but usually does not predict small-vessel organ damage.
The decision to order the test should therefore consider what action each possible result would trigger. If neither a positive nor a negative result would change the next diagnostic step, immediate ANCA testing may add little. When the result could direct an urgent kidney biopsy, chest evaluation, or vasculitis referral, it can be highly valuable.
Other Causes of a Positive ANCA Result
A positive ANCA result can arise outside primary AAV. The alternatives are especially important when the result is weak, atypical, or inconsistent with the patient’s organs.
Inflammatory bowel and autoimmune liver disease: Ulcerative colitis, Crohn disease, primary sclerosing cholangitis, and autoimmune hepatitis can produce atypical or perinuclear patterns. These often target antigens other than PR3 or MPO.
Infection: Infective endocarditis is a critical mimic because it can cause fever, purpura, kidney injury, positive ANCA, and low complement. Tuberculosis and chronic bacterial infections may also be associated with ANCA. Blood cultures and infection assessment should occur before immunosuppression when the presentation is compatible.
Medication or substance exposure: Hydralazine, propylthiouracil, methimazole, minocycline, and levamisole-contaminated cocaine can trigger ANCA and sometimes true vasculitis. Drug-induced profiles may include high MPO antibodies, dual MPO/PR3 positivity, ANA, anti-histone antibodies, and low complement.
Other autoimmune disease: Rheumatoid arthritis, lupus, and other connective-tissue diseases can produce ANCA or interfere with IFA interpretation. The result may represent overlap disease, nonspecific autoimmunity, or a separate drug reaction.
Chronic respiratory disease: Cystic fibrosis, bronchiectasis, and chronic airway infection can be associated with antibodies against bactericidal permeability-increasing protein and other neutrophil targets.
Laboratory variation: Weak results near the cutoff may not reproduce on a different platform. Sample handling, calibration, antigen presentation, and reader interpretation can all contribute.
The key question is not merely “What else causes ANCA?” It is “Which explanation best accounts for both the antibody and the organ findings?” A patient with atypical ANCA, chronic diarrhea, and cholestatic liver enzymes needs a different workup from a patient with PR3 antibodies, cavitary lung nodules, and active urine sediment.
Repeat Testing, Trends, and Disease Monitoring
Repeat ANCA testing can be useful, but it should answer a specific question. Repeating an unexpected borderline result before assigning a diagnosis is different from serially monitoring a patient with established AAV.
For diagnosis, repeat testing may be considered when:
- the first result is borderline or technically uncertain;
- IFA and PR3/MPO results conflict;
- the sample was drawn after treatment started;
- clinical suspicion remains high despite a negative result;
- the laboratory method changed;
- a medication or infection could have caused temporary positivity.
For established disease, changes in ANCA status may provide information about relapse risk, particularly in some PR3-positive patients. However, persistence, reappearance, or rising levels do not prove that a relapse is occurring. Some patients remain positive in remission, and others relapse without a clear rise.
Treatment decisions should therefore not rely on ANCA values alone. ACR guidance has favored scheduled maintenance dosing in relevant situations rather than changing rituximab solely in response to ANCA titers or B-cell counts. Clinicians look for symptoms, physical findings, creatinine trends, urine sediment, proteinuria, inflammatory markers, imaging changes, and other organ-specific evidence.
Use the same laboratory and assay for trends when possible. A numerical jump after a platform change may reflect different calibration rather than a biological change. The report should be compared with the laboratory’s current reference interval, not with an internet “normal range.”
Next Steps After an ANCA Result
The next step depends more on organ risk than on whether the result is simply labeled positive or negative.
After a positive result, clinicians commonly review the exact antigen, strength, pattern, medication list, infection symptoms, and previous results. They then look for objective organ involvement with tests such as:
- urinalysis with microscopy and urine protein measurement;
- creatinine and estimated glomerular filtration rate;
- CBC for anemia, eosinophilia, or other abnormalities;
- chest imaging for nodules, infiltrates, cavities, or hemorrhage;
- CRP and ESR as nonspecific measures of inflammation;
- complement C3 and C4 when immune-complex or drug-induced disease is possible;
- blood cultures or echocardiography when endocarditis is a concern;
- biopsy of kidney, skin, lung, nerve, sinus, or another involved site.
After a negative result, the clinician decides whether the remaining clinical probability is low enough to stop or whether the suspected organ disease still demands biopsy and specialist review. A negative test should not postpone treatment of a rapidly progressive pulmonary-kidney syndrome while diagnostic work continues.
Seek urgent medical assessment for coughing blood, rapidly worsening shortness of breath, low oxygen, dark or red urine, markedly reduced urine output, rapidly rising creatinine, new foot or wrist drop, severe eye pain with reduced vision, or widespread purpura with systemic illness. These signs can represent active organ-threatening disease whether ANCA is positive, negative, or pending.
A well-interpreted ANCA test is a probability tool. The pattern suggests where an antibody appears, PR3 or MPO identifies its main target, and the clinical evaluation determines whether the result represents vasculitis. Keeping those roles separate prevents both false reassurance from a negative test and overdiagnosis from an isolated positive one.
References
- Assessment of antineutrophil cytoplasmic antibodies (ANCA) 2025 (Recommendations)
- Diagnosis and management of ANCA-associated vasculitis 2024 (Review)
- ANCA-Negative Pauci-Immune Glomerulonephritis: A Review 2024 (Review)
- EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update 2024 (Guideline)
- Diagnosing and treating ANCA-associated vasculitis: an updated review for clinical practice 2023 (Review)
- The value of anti-neutrophil cytoplasmic antibodies (ANCA) testing for the diagnosis of ANCA-associated vasculitis, a systematic review and meta-analysis 2021 (Systematic Review)
Disclaimer
This article provides general information and cannot determine whether an individual has vasculitis. ANCA results require interpretation with symptoms, examination, medication history, infection assessment, urine studies, kidney function, imaging, and sometimes biopsy. Seek urgent care for signs of lung bleeding, rapidly worsening kidney function, severe breathing difficulty, or other acute organ injury.
